CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700. Published online 2017 July 6 DOI: https://doi.org/10.4143/crt.2017.280

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700

Link1

Link2 Link3

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Marie Wislez, Etienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel

Lung Cancer: Targets and Therapy. 2016;83

Link1

177P: Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

E. Kim, T. Usari, A. Polli, I. Lewis, K. Wilner

Journal of Thoracic Oncology. 2016;11(4):S134

Link1 Link2

174P: Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

K. Wilner, T. Usari, A. Polli, E. Kim

Journal of Thoracic Oncology. 2016;11(4):S133

Link1 Link2

Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

Yichen Zhang, Yixue Shao, Charles Stoecker, Lizheng Shi

. 2021;

Link1 Link2

FACTORS ASSOCIATED WITH CRIZOTINIB EFFICACY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING DIFFERENT ALK FUSION VARIANTS

Respirology. 2018;23:288-289

Link1 Link2

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Yabing Cao, Guangli Xiao, Xibin Qiu, Sheng Ye, Tongyu Lin

PLoS ONE. 2014;9(12):e114008

Link1

Clinical Outcome for EML4-ALK-Positive Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Platinum-Based Chemotherapy

M. Takeda, I. Okamoto, K. Sakai, H. Kawakami, K. Nishio, K. Nakagawa

Annals of Oncology. 2012;23:xi44

Link1 Link2

PCN54 COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER IN UNITED STATES

Y. Zhang, Y. Shao, L. Shi

Value in Health. 2020;23:S32

Link1 Link2

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

Evelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidge

Cancer. 2013;120(5):664-674

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.